1 / 17

Hepatitis B

Hepatitis B. Patricia D. Jones, M.D. November 13, 2009. Hepatitis B. Prototype member of the Hepadnaviridae family DNA virus Outer lipoprotein envelope with 3 glycoproteins – Hep B surface antigens (HBsAg) Viral nucleocapsid protein - Hep B core antigen (HBcAg)

amity
Download Presentation

Hepatitis B

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Hepatitis B Patricia D. Jones, M.D. November 13, 2009

  2. Hepatitis B • Prototype member of the Hepadnaviridae family • DNA virus • Outer lipoprotein envelope with 3 glycoproteins – Hep B surface antigens (HBsAg) • Viral nucleocapsid protein - Hep B core antigen (HBcAg) • Soluble nucleocapsid protein-Hepatitis B e antigen (HBeAg) http://pathmicro.med.sc.edu/virol/hep-b5.jpg

  3. Epidemiology • Worldwide: • Affects 350-400 million persons • Endemic areas: Asia, Africa • 1 million worldwide deaths per year • Acquired perinatally and in childhood • United States: • Affects 1.25 million persons • 4000-5000 deaths per year • Acquired via sexual activity, then IVDU and occupational exposure http://liver.stanford.edu/images/education/world_incidence.jpg

  4. Primary Infection • Incubation Period 4-10 weeks • During the prodromal period, patient may have a serum sickness-like syndrome. • Constitutional symptoms, anorexia, nausea, RUQ discomfort and jaundice. • 30 % develop icteric hepatitis. • 70% develop anicteric or subclinical hepatitis. • 0.5-1% develop fulminant liver failure. • Symptoms and jaundice disappear in 1-3 months, though fatigue may persist.

  5. Infection in Children vs. Adults • Children • In neonates, the immature immune system does not recognize a difference between the virus and the host. • Cellular immune responses to hepatocyte-membrane HBV proteins do not occur. • Risk of developing chronic HBV infection is 90% in infants born to HBeAg positive mothers. In children under 5, risk is 25-30%. • Adults: • Tend to have a more vigorous immune response. • Less than 5% of those infected develop continual viremia and persistent infection.

  6. Serologic Diagnosis

  7. http://www.haps.nsw.gov.au/userData/img//hepB1.jpg

  8. Chronic Hepatitis B Infection • Early Replicative Phase: Immune Tolerance • Perinatally acquired infection • High levels of HBV DNA, HBeAg present • No liver disease—normal ALT, asymptomatic, Stage 0-1 fibrosis • Lasts 10-30 years • Replicative Phase: Immune Clearance • Spontaneous clearance of HBeAg • Often characterized by periods of increased HBV DNA and increased ALT due to immune-mediated lysis of infected hepatocytes, i.e. flares • Nonreplication Phase: Inactive Carrier State • HBeAg negative, anti-Hep B e positive, HBV DNA undetectable • ALT levels normalize, however some patients may have active inflammation

  9. Chronic Hepatitis B Infection • HBeAg-negative Chronic Hepatitis • Precore/Core Promoter Mutations • Moderate levels HBV DNA • Active liver disease and elevated ALT • Older patients • Resolution • Hallmark is the clearance of HbSAg • Does not preclude development of cirrhosis, HCC or failure. • Patients may still produce HBV DNA, which has implications in the immunosuppressed

  10. Sequelae of Chronic HBV Infection • Cirrhosis • Hepatocellular Carcinoma • Hepatic Decompensation • Extrahepatic Manifestations • Death • Prognosis is worse in endemic areas: • Prolonged replicative phase • Clearance of HBeAg causes a 2 fold decrease in death rate. • Patients who reactivate have worse prognosis. http://pathmicro.med.sc.edu/lecture/images/hepato-b.jpg

  11. Extrahepatic Manifestations • Occur in 10-20% of patients with Chronic Hep B. • Serum Sickness • Polyarteritis Nodosa • Membranous and Membranoproliferative Glomerulonephritis

  12. Genotypes • Genotype B associated with HBeAg seroconversion at an earlier age, more sustained remission, less active hepatic necroinflammation, a slower rate of progression to cirrhosis and lower rate of HCC development when compared with Genotype C. • Genotypes A and B are associated with higher rates of seroconversion with pegIFN-alpha than C and D.

  13. Indications for Therapy Acute Hepatitis • One trial demonstrated no biochemical or clinical benefit in patients treated with Lamivudine vs. placebo in 12 months. • General Rule: • Coagulopathy INR>1.5 • Persistent symptoms or marked jaundice (bilirubin >10 mg/dl) for more than 4 weeks after presentation • Fulminant Hepatic Failure • Concomitant infection with Hep C or D

  14. Indications for Therapy HBeAg-positive patients: • HBeAg-positive patients with persistently normal ALT should be tested for ALT at 3-6 month intervals • HBeAg status should be checked every 6-12 months. • HBeAg positive with HBV DNA levels >20,000 IU/mL after a 3-6 month and ALT 1-2 x ULN OR are >40 years liver biopsy w/ treatment if biopsy shows moderate/severe inflammation or significant fibrosis. • Patients who remain HBeAg positive with HBV DNAlevels>20,000 IU/mL after a 3-6month period of elevated ALT levels >2 ULN should be considered for treatment. HBeAg-negative patients: • HBeAg-negative patients with normal ALT and HBV DNA <2,000 IU/mL: Tested ALT q 3months during the first year to verify true “inactive carrier state” and then every 6-12 months. http://www.aasld.org/practiceguidelines/Documents/Bookmarked%20Practice%20Guidelines/Chronic_Hep_B_Update_2009%208_24_2009.pdf

  15. http://knol.google.com/k/-/-/1w026jckgcwg2/18ad7q/slide4%20(1).jpghttp://knol.google.com/k/-/-/1w026jckgcwg2/18ad7q/slide4%20(1).jpg

  16. References: • Dienstag JL. Hepatitis B Virus Infection. N Eng J Med 2008;359: 1486-500. • Ganem D, Prince AM. Hepatitis B Virus Infection—Natural History and Clinical Consequences. N Eng J Med 2004; 350: 1118-29. • Liaw YF, Chu CM. Hepatitis B Virus Infection. Lancet 2009;373:582-592. • Lok ASF, McMahon BJ. Chronic Hepatitis B: Update 2009. Hepatology 2009; 3: 1-36. • Lok ASF. Clinical manifestations and natural history of hepatitis B virus infection. UpToDate

  17. Inspiration

More Related